Urothelial Cancer Clinical Trials

Find Urothelial Cancer Clinical Trials Near You

A Study to Evaluate 18F-N230A PET/CT Imaging of Nectin-4 Expression in Patients With Renal Cell Carcinoma and Renal Pelvic Urothelial Carcinoma

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Renal cell carcinoma and renal pelvic urothelial carcinoma are common malignant tumors of the urinary system. Accurate preoperative differentiation between these tumor types is important for treatment planning, while conventional imaging methods may have limitations in characterizing tumor biology. Nectin-4 is a tumor-associated molecular target that is highly expressed in several epithelial malignancies, particularly urothelial carcinoma. 18F-N230A is a novel PET imaging probe targeting Nectin-4. This study aims to evaluate the safety, biodistribution, and imaging characteristics of 18F-N230A PET/CT in patients with suspected or confirmed renal tumors. Participants enrolled in this study will undergo 18F-N230A PET/CT imaging and 18F-FDG PET/CT imaging. The imaging findings and quantitative parameters will be analyzed and compared. Pathological results obtained from surgery or biopsy will be used as the reference standard to evaluate the potential value of 18F-N230A PET/CT in differentiating renal cell carcinoma from renal pelvic urothelial carcinoma. This study may provide a new molecular imaging approach for improving the preoperative diagnosis of renal tumors and supporting individualized clinical decision-making.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Participants aged ≥18 years.

• Patients with suspected or confirmed renal tumors who are scheduled for pathological examination by biopsy or surgical resection within 2 months.

• Patients who can understand the study procedures and voluntarily provide written informed consent.

• Patients who can cooperate with PET/CT imaging procedures.

Locations
Other Locations
China
Peking University First Hospital
RECRUITING
Beijing
Contact Information
Primary
Jianhua Zhang
zjhjn820@163.com
86-10-83572791
Time Frame
Start Date: 2026-07-09
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 80
Treatments
Experimental: Experimental: 18F-N230A PET/CT Imaging
Participants with suspected or confirmed renal tumors will receive an intravenous injection of 18F-N230A followed by PET/CT imaging. Participants will also undergo 18F-FDG PET/CT imaging for comparison. PET/CT imaging findings will be analyzed and compared with pathological results obtained from surgery or biopsy to evaluate the diagnostic value of 18F-N230A PET/CT for differentiating renal cell carcinoma and renal pelvic urothelial carcinoma.
Sponsors
Leads: Peking University First Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials